Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy
Platinum drugs are heavily used first-line chemotherapeutic agents for many solid tumours and have stimulated substantial interest in the biological activity of DNA-binding metal complexes. These complexes generate DNA lesions which trigger the activation of DNA damage response (DDR) pathways that a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
John Wiley and Sons
2020
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/88194/ http://psasir.upm.edu.my/id/eprint/88194/1/ABSTRACT.pdf |